This morning, HitGen Inc., an enterprise located in Chengdu High-tech Zone, was listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange, becoming the first enterprise to land on it in Southwest China!

The company's securities are referred to as "HitGen" for short, and the security number is "688222". It will offer 40.68 million shares, aiming to raise fund RMB 834.7536 million in total.

HitGen plans to invest the raised funds on new molecular design, building and application of platform construction and construction of new drug R & D center.

 

HitGen is a drug discovery CRO company in Chengdu High-tech Zone, mainly working on customization service of DEL (DNA Encoded compound Library) library, DEL screening service, chemical synthesis service, transfer of new drug R&D project, etc. With 8 years of development, it has become one of the companies ranking the first echelon of the DEL technology industry. Up to now, there are more than 400 billion compounds in DNA coding small-molecule compound libraries.

 

Li Jin, founder and chairman, said that by 2020, the company planned to have trillions of molecules in the DNA coding compound libraries. The company will continually focus on investment in research and development of DEL technology and business development and increase investment in new drug R&D and innovation to build an internationally leading "seed bank" of innovative drugs and a "new engine" of new drug innovation with improving business values.

 

Photo: Sichuan Daily Observation

From the establishment to its Sci-Tech innovation board listing, it takes 8 years, which not only records a dream building trip of a mid-aged entrepreneur but also witnesses the development process of Chengdu High-tech Zone in building a world-class high-tech park.

 

In 2012

Li Jin established HitGen in Tianfu Life Science Park of Chengdu High-tech Zone. Soon after the establishment, a high standard laboratory covering an area of 1,500 square meters was completed, including several biological and chemical laboratories, chemical reagent libraries, etc., and it was supported by subsidies, such as venue, rent, decoration and so on from Chengdu High-tech Zone government.

"As a start-up enterprise, what in urgent need is a stable talent team and the support of the government. The professional team of Chengdu High-tech Zone offers clear policies and good service. They will definitely implement what we have negotiated and will take the initiative to fulfill the promised policy." Li Jin said.

 

In 2019

HitGen was officially moved to Chengdu Tianfu International Bio-town, where the company will build a new drug R&D center and a high standard new drug R&D site to advance the strength of new drug R & D.

We believe that the bio-town has a lot of room for development, and many biopharmaceutical companies will come in forming an excellent industrial chain.  Chengdu Tianfu International Bio-town is a representative of Chengdu industry zones.  Its success will mean a larger room for its future development.  In the future, we will continue to tap the biopharmaceutical industry, and continue to exploit Chengdu Tianfu International Bio-town.  

 

From its establishment in 2012 to today's Sci-Tech innovation board listing, HitGen was born and is growing in Chengdu Hi-tech Zone.

Its development is a microcosm of the development of nearly 140,000 enterprises in Chengdu Hi-tech Zone.  In order to better promote the innovation and development of enterprises, Chengdu Hi-tech Zone has established an industrial cultivation and service system covering the whole life cycle of enterprise development.

We believe that the bio-town has a lot of room for development, and many biopharmaceutical companies will come in forming an excellent industrial chain. Chengdu Tianfu International Bio-town is a representative of Chengdu industry zones. Its success will mean a larger room for its future development. In the future, we will continue to tap the biopharmaceutical industry, and continue to exploit Chengdu Tianfu International Bio-town.

 

 

Build a green channel
Implement the gradient cultivation and improvement of a library of reserve enterprises for listing

 

Chengdu Hi-tech Zone takes the docking to the multi-level capital market as an important support to achieve high quality development. It is making efforts to improve the library of reserve enterprises for listing by building a "green channel" of government services for enterprise listing, implementing gradient cultivation and providing classification services to unswervingly support enterprises to enter the capital market for further development.

 

 

Implement chain-wide policy services

Encourage and help enterprises toward successful listing

 

The reserve enterprises for listing in Chengdu Hi-tech Zone can receive preferential support from policy-oriented loan products such as "Park Guarantee Loan "," Growth Loan" and "Expansion Loan ", and from state-owned venture capital funds. In the process of stock reform, the natural shareholders of an enterprise can also enjoy the special service of "Stock Reform Loan", an innovative financial product, when they pay personal tax due to capital surplus and surplus reserve being transferred to share capital.

 

 Innovatively implement "Stock Reform Loan"

 Fully support enterprises to be listed on the Sci-Tech Innovation Board

 

In order to solve the problem of personal tax of HitGen's natural person shareholders, Chengdu Hi-tech Zone organized Bank of Chengdu to connect with HitGen, coordinate in solving their problems in credit information and foreign exchange management, and flexibly adjust the entry threshold of "Stock Reform Loan". Based on this, Chengdu High-tech Zone and Bank of Chengdu jointly optimized the introduction of "Stock Reform Loan" product plan to solve the problems of loans, credit support and financial support for small and micro enterprises and private enterprises.

 

Photographed by JOJO

Bioindustry exceeded RMB 50 billion for the first time in 2019

The main business income of its pharmaceutical industry amounts to RMB 24.3 billion accounting for 34.9% of the pharmaceutical industry in Chengdu, and has maintained a growth rate of nearly 20% for three consecutive years.

 There are 11 new varieties of RMB 100 million, up 26.8% from the same period last year.

 

There are 73 new drugs being developed, an increase of 40.4% over the same period last year. Among them, 27 have entered the clinical stage, accounting for more than 60% of Sichuan province.

 

Rapid development of enterprises in the zone attracts world-renowned enterprises to accelerate their layout here

 

 Brilliant Pharmaceutical, an enterprise in Chengdu High-tech Zone, has been selected in China's top 100 pharmaceutical industry list.

 

Hinova has fully launched the global phase III clinical study on its prostate cancer drug, which is expected to become Sichuan Province's first small molecular drug listed in the United States.

 

It has attracted Gilead Sciences (a world's top 500 company), Boston Scientific (a US top 500 company), IQVIA (a US top 500 company) and other world-renowned enterprises to accelerate their layout here.

 

 

The development of HitGen is a good example to show the first-class environment for innovation, entrepreneurship and business in Chengdu Hi-tech Zone.

 

Chengdu Hi-tech Zone is constantly releasing new momentum of development, reaching new heights of opening up, creating new ecology for industries. It is also working to provide better services for enterprises and further optimize its business environment and speed up its construction of a world-class high-tech zone.

Source: Media Center of Chengdu High-tech Zone